Home › Compare › FSRPF vs ABBV
FSRPF yields 4.48% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, FSRPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FSRPF + ABBV for your $10,000?
Frasers Property Limited, an investment holding company, develops, invests in, and manages a portfolio of real estate properties. The company's asset portfolio includes integrated, residential, hospitality, commercial and business parks, retail, and logistics and industrial properties in Singapore, Australia, Europe, China, Thailand, Southeast Asia, and internationally. It owns and/or operates serviced apartments and hotels in approximately 70 cities across Asia, Australia, Europe, the Middle East, and Africa. The company also acts as a sponsor of two real estate investment trusts (REITs) listed on the SGX-ST that comprises Frasers Centrepoint Trust, and Frasers Logistics & Commercial Trust focused on retail, commercial, and industrial properties; and one stapled trust listed on the SGX-ST that include Frasers Hospitality Trust focused on hospitality properties; and two REITs listed on the Stock Exchange of Thailand, which include Frasers Property (Thailand) Public Company Limited, a sponsor of Frasers Property Thailand Industrial Freehold & Leasehold REIT that focuses on industrial and logistics properties in Thailand, as well as Golden Ventures Leasehold Real Estate Investment Trust, which focuses on commercial properties. The company was formerly known as Frasers Centrepoint Limited and changed its name to Frasers Property Limited in February 2018. The company was incorporated in 1963 and is headquartered in Singapore.
Full FSRPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.